Helder Mota Filipe, president of the Portuguese Pharmaceutical Association, presented the CT-Luso project on 3 September at the FIP Cape Town 2024 - 82nd World Congress of Pharmacy and Pharmaceutical Sciences. September, at FIP Cape Town 2024 - 82nd World Congress of Pharmacy and Pharmaceutical Sciences, organised by the International Pharmaceutical Federation (FIP) in Cape Town, South Africa.
With the theme ‘Innovating for the Future of Healthcare’, the congress offers an opportunity for for pharmacy professionals from all over the world to come together, exchange knowledge and discuss innovations in the field of healthcare.
In this context, president Hélder Mota Filipe emphasised the importance of the mission of the CT Luso project project, which aims to train health professionals from Portuguese-speaking countries in biomedical research and clinical trials. clinical trials.
‘Data from 2022 shows that Africa carried out only 1% (861) of clinical trials worldwide, compared to 22 per cent (13,066) in Europe,’ he said. South Africa, Kenya and Nigeria responsible for 63.75 per cent of the clinical trials carried out on the African continent.
These figures demonstrate that ‘Portuguese-speaking countries are often excluded from the clinical trial circuit’, with the ’language barrier being one of the main causes of this marginalisation. Clinical research training is usually conducted in English or French’.
The CT-Luso project is funded by the European Commission through the EDCTP3 Programme, a Partnership between Europe and Developing Countries.
